Acro Biomedical Co., Ltd.

What they do

Since a January 30, 2017 change of control, Acro Biomedical has been in the business of developing and marketing nutritional products, historically cordyceps-related products purchased from three suppliers in Taiwan and sold to four unrelated customers. Cordyceps is a fungus used in traditional Chinese medicine. The company also sold metallothionein MT-3 elizer in one 2018 quarter, a product it no longer sells. All sales to date were made by former CEO Pao-Chi Chu, who resigned August 14, 2025.

Revenue drivers

• Cordyceps-related nutritional products — Substantially all historical sales were cordyceps products; revenue was $1.2M in 2021 and $658,500 in 2022, and $0 in 2023, 2024 and 2025.
• Metallothionein MT-3 elizer — Sold only in the quarter ended June 30, 2018 (10-K) or September 30, 2018 (10-Q); the company does not currently sell this product.
• Customer concentration in Hong Kong/PRC channel — Four unrelated customers; two accounted for all 2022 sales and 91.7% of 2021 sales, and the 2017-2018 Hong Kong customers have not purchased since the quarter ended December 31, 2018.
• Proposed cordyceps-infused chicken feed — A research and development project pursued with consultants from May 2021 through August 2023 that did not generate a marketable product; no plans to recommence development.

Recent performance

The company reported no revenue for 2023, 2024 or 2025, and quarterly revenue was $0 in each of the four most recent quarters through June 30, 2026. Net losses were approximately $42,297 in 2024 and $101,146 in 2025, following losses of $7.7M in 2021, $15.9M in 2022 and $8.8M in 2023. Operating cash flow was negative $36,692 in 2024 and negative $196,302 in 2025. At June 30, 2026, total assets and cash were both $3,648 and shareholder equity was negative $444,789. Total liabilities were $326,946 at December 31, 2024.

Strategy

Management states it intends to recommence operations but has not generated sales since December 31, 2022 and has no orders for products or purchase orders from suppliers as of the filings. The business plan is described as in the preliminary stages and requires significant funding to implement. The company's sole source of financing since January 1, 2021 has been primarily a minority stockholder and, to a lesser extent, its chief executive officer, and it continues to rely on advances from the minority stockholder. It may seek equity financing but has no agreements or understandings for any funding. No full-time employees remain; the CEO serves part-time without compensation.

Risks

• No revenue and going-concern pressure — The company has had no sales since December 31, 2022, incurred a $101,146 loss in 2025, and states it may not be able to continue in business without funding.
• Dependence on related-party funding — Financing since January 1, 2021 has come primarily from a minority stockholder and, to a lesser extent, the chief executive officer, with no assurance those advances continue.
• Illiquid, quote-less common stock — The stock trades on the OTC Markets Expert Market or Pink Limited Market, is not eligible for proprietary broker-dealer quotes, has no market makers, and any equity raise would cause significant dilution.
• Customer and supplier concentration with no current pipeline — Two customers accounted for all 2022 sales and 91.7% of 2021 sales, the 2017-2018 Hong Kong customers stopped purchasing after 2018, and the company has no current orders or supplier purchase orders.

Outlook

Management says it intends to recommence operations and may seek to market complementary products, but it has entered no negotiations for additional products and cannot assure any will be marketable. It states the business plan is preliminary, requires significant funding, and that there is no assurance it can implement the plan or ever generate revenue or operate profitably. The company also cites COVID-19, China's former Zero COVID policy, and political instability in Hong Kong as factors affecting potential revenue.